Want to see SI full AI Analyst Report?
Earnings Data
Report Date
Sep 15, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.46Last Year’s EPS
-165.53Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a strong operating and commercial momentum: sizable revenue and volume growth, improving gross margins, accelerating surgeon adoption and meaningful product and technology milestones (I-135 full launch, N22 limited release, >500 patients in registry, and a progressing robotic partnership). These positives were offset by increased operating expenses and larger net and adjusted EBITDA losses as the company invests to scale, a Q1 cash burn driven by inventory and working capital, and some seasonality and ASP/mix variability risk embedded in the updated guidance. Overall, management expressed high conviction in the trajectory and raised full-year guidance while noting near-term investment-related impacts.Company Guidance
Strong Top-Line Growth
Net revenue of $16.7M in Q1 2026, up 65% year-over-year and 16% sequentially, driven by new surgeon adoption, increased utilization and higher ASPs.
Raised Full-Year Guidance
Full-year 2026 net revenue guidance increased to $65M–$68M, representing growth of 37%–44% versus 2025 (prior guide $62M–$65M, or 31%–37%).
High and Improving Gross Margins
Reported gross margin of 77.7% in Q1 2026 versus 76.9% in the prior year; management expects similar margins for the balance of 2026 with further improvement potential from cost-down programs.
Large Volume and Surgeon Adoption Gains
Total implant volume of 2,184 units in Q1, up 51% year-over-year; core and contender surgeon count was 134 at end of 2025 (up 61% YoY); the company more than doubled the number of new customers entering its funnel versus Q1 2025.
Commercial / Educational Momentum
44 SI-sponsored educational events in Q1; 2026 Napa symposium attendance up >70% year-over-year and >70% of non-customer attendees have already performed or committed to first/increased cases shortly after the meeting.
Product and Technology Milestones
I-135RFX humeral stem moved from limited release to full commercial launch with expanded fracture indications; initiated limited release of N22 Glenosphere; >500 patients enrolled in clinical registry; micro-robotic partnership progressing faster than expected with 510(k) targeted in 2027.
Strong Cash Position and Proactive Fulfillment
Cash and cash equivalents of $108.5M as of March 31, 2026; proactively increased inventory and asset purchases to support accelerated growth and avoid supply constraints; management expects materially lower cash burn beginning in Q2.
SI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | $13.53 | $15.59 | +15.23% |
Feb 12, 2026 | $13.72 | $13.06 | -4.81% |
Nov 11, 2025 | $11.36 | $15.00 | +32.04% |
Sep 09, 2025 | $15.90 | $14.98 | -5.79% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Shoulder Innovations, Inc. (SI) report earnings?
Shoulder Innovations, Inc. (SI) is schdueled to report earning on Sep 15, 2026, Before Open (Confirmed).
What is Shoulder Innovations, Inc. (SI) earnings time?
Shoulder Innovations, Inc. (SI) earnings time is at Sep 15, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SI EPS forecast?
SI EPS forecast for the fiscal quarter 2026 (Q2) is -0.46.
